Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats

Journal of Pharmacokinetics and Biopharmaceutics

Volumn 27, Issue 1, 1999, Pages 1-21

  Ferron, Geraldine M ^a,b   Pyszczynski, Nancy A ^a   Jusko, William J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b WYETH AYERST RESEARCH   (United States)

Author keywords

Cell trafficking; Drug interaction; Drug metabolism; PK PD model; Rat; T cytotoxic cells; T helper cells; Whole blood lymphocyte proliferation

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE; RAPAMYCIN;

ADRENALECTOMY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE PROLIFERATION; MALE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT;

ADRENAL GLANDS; ADRENALECTOMY; ANIMALS; BIOLOGICAL MARKERS; GLUCOCORTICOIDS; IMMUNOSUPPRESSIVE AGENTS; MALE; MICROSOMES, LIVER; MODELS, BIOLOGICAL; PREDNISOLONE; RATS; RATS, SPRAGUE-DAWLEY; SIROLIMUS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 0032782932     PISSN: 0090466X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020626611479     Document Type: Article

References (45)

1. A. S. Shoker. Immunopharmacologic therapy in renal transplantation. Pharmacotherapy 16:562-575 (1996).
2. R. Morris, Rapamycins: Antifungal, antitumor, antiproliferative, and immunosuppressive macrolides. Transpl. Rev. 6:39-87 (1992).
3. A. S, Fauci, D. C. Dale, and J. E. Balow. Glucocorticosteroid therapy: Mechanism of action and clinical considerations. Ann. Intern. Med. 84:304-315 (1976).
4. E. Bloemena, S. Weinreich, and P. T. A. Schellekens. The influence of prednisolone on the recirculation of peripheral blood lymphocytes in vivo. Clin. Exp. Immunol. 80:460-466 (1990).
5. M. Scudeletti, L. Castagnetta, B. Imbimbo, F. Puppo, I. Pierri, and F. Indiveri. New glucocorticoids: Mechanisms of immunological activity at the cellular level and in the clinical setting. Ann. N. Y. Acad. Sci. 595:368-382 (1990).
6. M. G. Murgia, S. Jordan, and B. Kahan. The side effect profile of sirolimus: A phase I study in quiescent cyclosporin-prednisone-treated renal transplant patients. Kidney Int. 49:209-216 (1996).
7. D. E. Hricik, W. Y. Almawi, and T. B. Strom. Trends in the use of glucocorticoids in renal transplantation. Transplantation 57:979-989 (1994).
8. G. Schmidbauer, W. W. Hancock, B. Wasowska, A. M. Badger, and J. W. Kupiec-Weglinski. Abrogation by rapamycin of accelerated rejection in sensitized rats by inhibition of alloantibody responses and selective suppression of intragraft mononuclear and endothelial cell activation, cytokine production, and cell adhesion. Transplantation 57:933-941 (1994).
9. G. M. Ferron and W. J. Jusko. Species- and gender-related differences in cyclosporine/prednisolone/sirolimus interactions in whole blood lymphocyte proliferation assays. J. Pharmacol. Exp. Ther. 286:191-200 (1998).
10. M. Sattler, P. Guengerich, C.-H. Yun, U. Christians, and K.-F. Sewing. Cytochrome P450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab. Dispos. 20:753-761 (1992).
11. F. J. Frey and B. M. Frey. Urinary 6β-hydroxyprednisolone excretion indicates enhanced prednisolone catabolism. J. Lab. Clin. Med. 101:593-604 (1983).
12. I. A. Shah, P. H. Whiting, G. Omar, A. W. Thomson, and M. D. Burke. Effects of FK506 on human hepatic microsomal cytochrome P-450-dependent drug metabolism in vitro. Transpl. Proc. 23:2783-2785 (1991).
13. Y. M. Ning and E. R. Sanchez. Potentiation of glucocorticoid receptor-mediated gene expression by the immunophilin ligands FK506 and rapamycin. J. Biol. Chem. 268:6073-6076 (1993).
14. Y. M. Ning and E. R. Sanchez, Stabilization in vitro of the untransformed glucocorticoid receptor complex of S49 lymphocytes by the immunophilin ligand FK506. J. Steroid Molec. Biol. 52:187-194 (1994).
15. Y. M. Ning and E. R. Sanchez. Immunophilins, heat shock proteins, and glucocorticoid receptor actions in vivo. Methods. 9:188-200 (1996).
16. G. Powis, I. Jardine, R. Van Dyke, R. Weinshilboum, D. Moore, T. Wilke, W. Rhodes, R. Nelson, L. Benson, and C. Szumlanski. Foreign compound metabolism studies with human liver obtained as surgical waste. Relation to donor characteristics and effects of tissue storage. Drug Metab. Disp. 16:582-589 (1988).
17. W. J. Jusko, N. A. Pyszczynski, M. S. Bushway, R. D'Ambrosio, and S. M. Mis. Fifteen years of operation of high-performance liquid chromatographic assay for prednisolone, cortisol and prednisone in plasma. J. Chromatog. B. 658:47-54 (1994).
18. G. M. Ferron, W. D. Conway, and W. J. Jusko. Lipophilic benzamide and anilide derivatives as high-performance liquid chromatography internal standards: Application to sirolimus (rapamycin) determination. J. Chromatog. B. 703:243-251 (1997).
19. V. Garg and W. J. Jusko, Bioavailability and reversible metabolism of prednisone and prednisolone in man. Biopharm. Drug Disp. 15:163-172 (1994).
20. V. G. Hale and L. Z. Benet. Prednisolone and prednisone exhibit linear extraction in the perfused rabbit liver. Drug Metab. Disp. 19:87-93 (1991).
21. R. Murata, D. B. Haughey, and W. J. Jusko. Effects of thyroid dysfunction on prednisolone and prednisone interconversion and disposition in the rat. Drug Metab. Disp. 18:403-408 (1990).
22. S. M. Abel, J. L. Maggs, D. J. Back, and B. K. Park. Cortisol metabolism by human liver in vitro - I. Metabolite identification and inter-individual variability. J. Steroid Biochem. Molec. Biol. 43:713-719 (1992).
23. Y.-N. Sun and W. J. Jusko. Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics, J. Pharm. Sci. 87:732-737 (1998).
24. R. Yatscoff, D. LeGatt, R. Keenan, and P. Chackowsky. Blood distribution of rapamycin. Transplantation 56:1202-1206 (1993).
25. J. Mordenti. Man versus beast: Pharmacokinetic scaling in mammals. J Pharm. Sci. 11:1028-1040 (1986).
26. J.-L. Steimer, A. Mallet, J.-L. Golmard, and J.-F. Boisvieux. Alternative approaches to estimation of population pharmacokinetic parameters: Comparison with the NONlinear Mixed-Effect Model. Drug Metab. Rev. 15:265-292 (1984).
27. A. Nichols, R. D'Ambrosio, N. A. Pyszczynski, and W. J. Jusko, Pharmacokinetics and pharmacodynamics of prednisolone in obese rats. J. Pharmacol. Exp. Ther. 250:963-970 (1989).
28. F. D. Boudinot and W. J. Jusko. Dose-dependent pharmacokinetics of prednisolone in normal and adrenalectomized rats. J. Pharmacokin. Biopharm. 14:453-467 (1986).
29. G. M. Ferron and W. J. Jusko. Species differences in sirolimus stability in humans, rabbits and rats. Drug Metab. Dispos. 26:83-84 (1998).
30. F. S. Chow, W. Piekoszewski, and W. J. Jusko. Effect of hematocrit and albumin concentration on hepatic clearance of tacrolimus (FK506) during rabbit liver perfusion. Drug Metab. Dispos. 25:610-616 (1997).
31. N. Honcharik, J. Fryer, and R. Yatscoff. Pharmacokinetics of rapamycin: Single-dose studies in the rabbit. Ther. Drug Monit. 14:475-478 (1992).
32. R. W. Yatscoff, P. Wang, K. Chan, D, Hicks, and J. J. Zimmerman. Rapamycin: Distribution, pharmacokinetics and therapeutic range investigations. Ther. Drug Monit. 17:666-671 (1995).
33. G. M. Ferron, E. V. Mishina, J. J. Zimmerman, and W. J. Jusko. Population pharmacokinetics of sirolimus in kidney transplant patients. Clin. Pharmacol. Ther. 61:416-428 (1997).
34. A. Gascon, B. Calvo, R. M. Hernandez, A. Dominguez-Gil, and J.-L. Pedraz. Interspecies scaling of cimetidine-theophylline pharmacokinetic interaction: Interspecies scaling in pharmacokinetic interactions. Pharm. Res. 11:495 (1994).
35. W. J. Jusko, G. M. Ferron, S. M. Mis, B. D. Kahan, and J. J. Zimmerman. Pharmacokinetics of prednisolone during administration of sirolimus in patients with renal transplants. J. Clin. Pharmacol. 36:1100-1106 (1996).
36. D. J. Waxman, C. Attisano, F. P. Guengerich, and D. P. Lapenson. Human liver microsomal steroid hormone 6β-hydroxylase cytochrome P-450 enzyme. Arch. Biochem. Biophys. 263:424-436 (1988).
37. R. M. Zürcher, B, M. Frey, and F. J. Frey. Impact of ketoconazole on the metabolism of prednisolone. Clin. Pharmacol. Ther. 45:366-372 (1989).
38. V. G. Hale and L. Z. Benet. The interconversion of prednisone and prednisolone in human and rabbit organs in vitro is a function of tissue integrity. Pharmacol. 44:273-282 (1992).
39. P. Schmiedlin-Ren, D. J. Edwards, M. E. Fitzsimmons, K. He, K. S. Lown, P. M. Woster, A. Rahman, K. E. Thummel, J. M. Fisher, P. F. Hollenberg, and P. B. Watkins. Mechanisms of enhanced oral availability of CYP3A substrates by grapefruit constituents: Decreased enterocyte CYP3A concentration and mechanism-based inactivation by furanocoumarins. Drug Metab. Dispos. 25:1228-1233 (1997).
40. R. Sackstein and M. Borenstein. The effects of corticosteroids on lymphocyte recirculation in humans: Analysis of the mechanism of impaired lymphocyte migration to lymph node following methylprednisolone administration. J. Invest. Med. 43:68-77 (1995).
41. J. Wald and W. J. Jusko. Prednisolone pharmacodynamics: Leukocyte trafficking in the rat. Life Sci. 55:371-378 (1994).
42. M. Milad, E. A. Ludwig, S. Anne, E. Middleton, and W. J. Jusko. Pharmacodynamic model for joint exogenous and endogenous corticosteroid suppression of lymphocyte trafficking. J. Pharmacokin. Biopharm. 22:469-480 (1994).
43. W. Pickoszewski, F. S. Chow, and W. J. Jusko. Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. J. Pharmacol. Exp. Ther. 269:103-109 (1994).
44. E. Bloemena, M. Roos, J. L. Van Heijst, J. M. Roosen, and P. T. A. Schellenkens. Whole-blood lymphocyte cultures. J. Immunol. Meth. 122:161-167 (1989).
45. S. N. Sehgal. Rapamune (sirolimus, rapamycin): An overview and mechanism of action. Ther. Drug Monit. 17:660-665 (1995).